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ORIGINAL ARTICLE
Background: Recent research on the US opioid epidemic has focused 
on the white or total population and has largely been limited to data 
after 1999. However, understanding racial differences in long-term 
trends by opioid type may contribute to improving interventions.
Methods: Using multiple cause of death data, we calculated age-
standardized opioid mortality rates, by race and opioid type, for the 
US resident population from 1979 to 2015. We analyzed trends in 
mortality rates using joinpoint regression.
Results: From 1979 to 2015, the long-term trends in opioid-related 
mortality for Earlier data did not include ethnicity so this is incorrect. 
It is all black and all white residents in the US. blacks and whites 
went through three successive waves. In the first wave, from 1979 
to the mid-1990s, the epidemic affected both populations and was 
driven by heroin. In the second wave, from the mid-1990s to 2010, 
the increase in opioid mortality was driven by natural/semi-synthetic 
opioids (e.g., codeine, morphine, hydrocodone, or oxycodone) 
among whites, while there was no increase in mortality for blacks. In 
the current wave, increases in opioid mortality for both populations 
have been driven by heroin and synthetic opioids (e.g., fentanyl and 
its analogues). Heroin rates are currently increasing at 31% (95% 
confidence interval [CI] = 27, 35) per year for whites and 34% (95% 
CI = 30, 40) for blacks. Concurrently, respective synthetic opioids 
are increasing at 79% (95% CI = 50, 112) and 107% (95% CI = −15, 
404) annually.
Conclusion: Since 1979, the nature of the opioid epidemic has 
shifted from heroin to prescription opioids for the white population 
to increasing of heroin/synthetic deaths for both black and white 
populations. See video abstract at, http://links.lww.com/EDE/B377.
Keywords: Opioids, Racial disparities, Joinpoint analysis, Substance 
abuse
(Epidemiology 2018;29: 707–715)
Since 1979, the opioid mortality rate has increased 22-fold in the United States, resulting in over 33,000 deaths in 
2015 alone, drawing national attention and becoming an 
important part of the political agenda.1,2 The continuous inten-
sification of fatal overdoses is unique to opioids, as the rate 
of all nonopioid drug overdoses, though doubling from 1979 
to 2006, has remained constant since then (eFigure 1; http://
links.lww.com/EDE/B356 and eTable 1; http://links.lww.com/
EDE/B356).
In the 1990s and 2000s, the epidemic was driven by pre-
scription opioids3,4 as part of aggressive marketing tactics by 
the pharmaceutical industry and changing medical standards 
in diagnosis and treatment of chronic pain.5,6 However, clini-
cal behaviors (i.e., prescription patterns and pain management) 
differ markedly by race,7,8 with much lower opioid prescription 
rates in the black population than in the white population.9,10 
In addition, the extent of racial bias in prescribing patterns has 
been found to vary by physician characteristics such as gender 
and race.11,12 This differential clinician behavior is important 
because prescription opioid misuse is a substantial risk factor 
for heroin use.13 Recent research has suggested that rates of 
heroin use and prescription opioid misuse in blacks and whites 
have begun to converge in recent years.14–16 However, the con-
vergence and divergence of opioid mortality rates by race over 
longer time periods have not been explored.
Recent research describes the opioid epidemic as hav-
ing been initially driven by prescription opioids starting in the 
mid-1990s, followed by a continuing rise in the number of 
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heroin deaths starting in the mid-2000s, concurrently fueled 
by illicitly manufactured synthetic opioids such as fentanyl, 
starting around 2013.17–19 However, these studies have largely 
been limited to opioid mortality in the total or white popula-
tion after 1999, with only more recent work focusing on the 
opioid epidemic in the black population.20 We aim to supple-
ment the current literature by describing black- and white-spe-
cific opioid mortality trends from 1979 to 2015. To date, this is 
the longest period of analysis of opioid mortality in the United 
States, contributing an expanded perspective on trends over 
time and allowing for the examination of mortality by race 
and opioid type to understand the factors behind these trends.
METHODS
Multiple Cause of Death Data
We used a publicly available microlevel dataset with 
multiple causes of death derived from all the death certifi-
cates collected in the United States by the National Center for 
Health Statistics from 1979 to 2015.21 For death certificates 
related to fatal overdoses, state laws require all contributing 
substances be identified, and where possible, a single agent 
to be specified as the underlying cause of death. In addition, 
up to 20 other contributory causes can be listed on the death 
certificate. The presence of a drug is not sufficient for the drug 
to be deemed the underlying cause; therefore, both the under-
lying and contributory causes must be considered when iden-
tifying deaths from drug overdose.4,22
Death certificates are coded by the National Center for 
Health Statistics to produce multiple cause of death data.21 
Over the period 1979–1998, deaths were classified according 
to the Ninth Revision of the International Classification of 
Diseases (ICD-9),23 while the Tenth Revision (ICD-10)24 has 
been implemented since 1999.
Defining Opioid-Related Deaths
We defined overdoses involving opioids as specified in 
the Consensus recommendations for national and state poi-
soning surveillance (eTable 2; http://links.lww.com/EDE/
B356).25 Specifically, for 1979–1998, an opioid overdose was 
defined as a death with at least one of the following ICD-9 
codes for either the underlying cause or for one of the contrib-
utory causes: E850.0 (heroin), E850.1 (methadone), E850.2 
(other pharmaceutical opioid), or N965.0 (undetermined/
unknown opioid).
For 1999–2015, all opioid overdoses were defined by a 
combination of specific codes for the underlying cause and at 
least one relevant contributory cause code. The ICD-10 codes 
for the underlying cause corresponding to overdoses are X40–
X44, X60–X64, X85, and Y10–Y14. In addition, for a death 
to be defined as opioid related, it has to include one or more of 
the following ICD-10 codes: opium (T40.0); heroin (T40.1); 
other natural and semi-synthetic (T40.2) such as codeine, 
morphine, hydrocodone, or oxycodone; methadone (T40.3); 
other synthetic (T40.4) such as tramadol, fentanyl, and fen-
tanyl derivatives; or unspecified (T40.6).
Statistical Analysis
Using the multiple cause of death data, we tabulated 
deaths from opioid overdose for the total, black, and white 
resident populations by five-year age groups (i.e., 0–4, 5–9, 
…, 85+). In addition, we tabulated these deaths by type of 
opioid. Due to the changes in the coding of opioid types from 
TABLE 1. Joinpoint Regression Results by Race and Broad Opioid Type, 1979–2015
 
Observed Valuea
Average APC Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 Trend 61979 2015
Rate 95% CI Rate 95% CI AAPC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI
Rate ratiob 0.71 0.58, 0.84 1.9 1.8, 1.9 3 2, 4 1979–1993 −1 −3, 1 1993–2010 9 8, 10 2010–2015 −6 −9, −3          
All opioids
  White 0.44 0.41, 0.47 12 12, 12 10 9, 11 1979–1989 8 5, 12 1989–2006 13 12, 13 2006–2013 5 3, 6 2013–2015 15 6, 25       
  Black 0.62 0.52, 0.72 6.6 6.3, 6.8 6 5, 7 1979–1994 11 9, 13 1994–2011 0 0, 1 2011–2015 16 10, 23          
Heroin
  White 0.14 0.12, 0.15 4.8 4.7, 4.9 12 10, 14 1979–1998 12 10, 13 1998–2005 1 −4, 6 2005–2010 12 3, 22 2010–2015 31 26, 36       
  Black 0.33 0.25, 0.40 3.1 2.9, 3.3 7 6, 9 1979–1995 8 6, 10 1995–2010 0 −2, 1 2010–2015 33 27, 40          
Methadone
  White 0.053 0.042, 0.063 1.2 1.2, 1.2 2 −1, 4 1979–1988 −2 −6, 3 1988–1998 −9 −15, −4 1998–2003 43 37, 49 2003–2006 20 12, 30 2006–2011 −5 −7, −3 2011–2015 −8 −11, −6
  Black 0.036 0.0080, 0.063 0.58 0.51, 0.65 0 −5, 3 1979–1987 2 −9, 14 1987–1999 −13 −20, −4 1999–2006 24 18, 29 2006–2009 −9 −25, 19 2009–2015 −2 −5, 2    
Other
  White 0.25 0.23, 0.28 8.2 8.0, 8.3 9 4, 15 1979–1990 8 2, 14 1990–1993 23 −30, 118 1993–2010 9 8, 10 2010–2013 −1 −17, 18 2013–2015 18 1, 39    
  Black 0.26 0.19, 0.33 4.2 4.0, 4.4 7 5, 10 1979–1994 15 10, 19 1994–2013 0 −2, 1 2013–2015 34 2, 77          
aAll observed values are expressed as rates per 100,000 except the rate ratio.
bRate ratio is the white opioid mortality rate divided by the black opioid mortality rate.
AAPC indicates average annual percent change; APC annual percent change; CI, confidence interval.
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ICD-9 to ICD-10, we defined three temporally stable opioid 
categories as (a) opioid deaths involving heroin, (b) opioid 
deaths involving methadone, and (c) opioid deaths involving 
an opioid other than (but not excluding) heroin or methadone. 
We refer to these categories as “heroin”, “methadone”, and 
“other” throughout the text; however, note that multiple opi-
oids could be listed on death certificates coded with the ICD-
10, and thus these categories are not mutually exclusive. The 
“other” category covers natural/semisynthetic, synthetic, and 
unspecified opioid types. For the ICD-10 years (1999–2015), 
we additionally tabulated deaths by type of opioid using the 
more specific ICD-10 categories defined above. To estimate 
the denominator of the rates, we used national race- and 
age-specific annual population estimates from the US Cen-
sus Bureau’s Population Estimates Program. All rates are 
expressed as the number of deaths per 100,000 people and 
directly age-standardized to the US 2000 population. Standard 
errors for the rates were obtained using a Poisson approxi-
mation.26,27 We calculated the opioid rate ratio as the rate for 
whites divided by the rate for blacks and estimated standard 
errors for the ratio using the delta approximation.28
We used joinpoint regression to examine trends in the 
age-standardized rates and rate ratio calculated as described 
above via the Joinpoint Regression Program version 4.5.0.1.29 
Using a segmented weighted least squares regression, the pro-
gram iteratively adds joinpoints and finds the model with the 
optimal number of joinpoints, between zero and five, selecting 
the model that best fits the data. Model fit is evaluated using a 
permutation test.30 To account for the ICD-9 to ICD-10 cod-
ing change, an indicator variable was used for years ≥1999 
for models spanning the entire period (see eTables 3–8; http://
links.lww.com/EDE/B356 for full joinpoint model results). 
For the best model in each case, we report the annual percent 
change as well as the average annual percent change for the 
entire period under analysis. The average annual percentage 
change is defined as the weighted average of the annual per-
centage changes, with weights equal to the number of years in 
each time segment. Summary results are presented in Table 1 
and Table 2. The code to reproduce tables and figures are 
available online (eText 1; http://links.lww.com/EDE/B356). 
This study was reviewed by the Harvard TH Chan School of 
Public Health institutional review board and did not require 
full review because it uses publicly available, retrospective, 
de-identified data.
RESULTS
From 1979 to 2015, the opioid mortality rate for whites 
increased from 0.44 to 12, corresponding to an average 
increase of 10% (95% confidence interval [CI] = 9, 11) per 
year. Over the same period, the rate for blacks increased from 
0.62 to 6.6 for an average annual increase of 6% (95% CI = 5, 
7). While the rate for whites increased steadily over the whole 
period, the rate for blacks remained stable in 1994–2011 
(Table 1 and Figure 1). This differential growth is reflected 
in changes in the rate ratio (white to black mortality) through 
three successive waves. The rate ratio was approximately 0.71 
from 1979 to 1993, then increased by 9% (95% CI = 8, 10) per 
year to over 2 by 2010 and declined thereafter by −6% (95% 
CI = −9, −3) annually to reach 1.9 in 2015 (Figure 1).
We examined trends in mortality by broad opioid cat-
egory (heroin, methadone, and other) to identify the drivers of 
change in the rate ratio. Both blacks and whites experienced 
TABLE 1. Joinpoint Regression Results by Race and Broad Opioid Type, 1979–2015
 
Observed Valuea
Average APC Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 Trend 61979 2015
Rate 95% CI Rate 95% CI AAPC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI Years APC 95% CI
Rate ratiob 0.71 0.58, 0.84 1.9 1.8, 1.9 3 2, 4 1979–1993 −1 −3, 1 1993–2010 9 8, 10 2010–2015 −6 −9, −3          
All opioids
  White 0.44 0.41, 0.47 12 12, 12 10 9, 11 1979–1989 8 5, 12 1989–2006 13 12, 13 2006–2013 5 3, 6 2013–2015 15 6, 25       
  Black 0.62 0.52, 0.72 6.6 6.3, 6.8 6 5, 7 1979–1994 11 9, 13 1994–2011 0 0, 1 2011–2015 16 10, 23          
Heroin
  White 0.14 0.12, 0.15 4.8 4.7, 4.9 12 10, 14 1979–1998 12 10, 13 1998–2005 1 −4, 6 2005–2010 12 3, 22 2010–2015 31 26, 36       
  Black 0.33 0.25, 0.40 3.1 2.9, 3.3 7 6, 9 1979–1995 8 6, 10 1995–2010 0 −2, 1 2010–2015 33 27, 40          
Methadone
  White 0.053 0.042, 0.063 1.2 1.2, 1.2 2 −1, 4 1979–1988 −2 −6, 3 1988–1998 −9 −15, −4 1998–2003 43 37, 49 2003–2006 20 12, 30 2006–2011 −5 −7, −3 2011–2015 −8 −11, −6
  Black 0.036 0.0080, 0.063 0.58 0.51, 0.65 0 −5, 3 1979–1987 2 −9, 14 1987–1999 −13 −20, −4 1999–2006 24 18, 29 2006–2009 −9 −25, 19 2009–2015 −2 −5, 2    
Other
  White 0.25 0.23, 0.28 8.2 8.0, 8.3 9 4, 15 1979–1990 8 2, 14 1990–1993 23 −30, 118 1993–2010 9 8, 10 2010–2013 −1 −17, 18 2013–2015 18 1, 39    
  Black 0.26 0.19, 0.33 4.2 4.0, 4.4 7 5, 10 1979–1994 15 10, 19 1994–2013 0 −2, 1 2013–2015 34 2, 77          
aAll observed values are expressed as rates per 100,000 except the rate ratio.
bRate ratio is the white opioid mortality rate divided by the black opioid mortality rate.
AAPC indicates average annual percent change; APC annual percent change; CI, confidence interval.
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an increase in heroin and other opioid mortality over the full 
period (Table 1 and Figure 2). In 1979, the heroin mortality 
rate was 0.14 for whites and 0.33 for blacks. By 2015, the 
heroin mortality rates had risen to 4.8 for whites and 3.1 for 
blacks, resulting in average annual increases of 12% (95% CI 
= 10, 14) for whites and 7% (95% CI = 6, 9) for blacks. The 
general pattern of increase in heroin mortality was similar for 
both populations: the rates first grew relatively slowly up to 
the 1990s, reaching a plateau in 1995 for blacks and 1998 for 
whites, before accelerating after 2005 for whites and 2010 for 
blacks. Between 2010 and 2015, the annual percent change in 
heroin mortality reached over 30% for both populations.
The mortality rate from other opioids increased from 
approximately 0.25 for each of the two populations to 8.2 for 
whites and 4.2 for blacks. In contrast to heroin mortality, the 
trends in other opioid mortality over the period differ mark-
edly by race. For whites, the rate increased substantially in 
1993–2010, while for blacks, it remained stable during this 
period. However, during 2013–2015, mortality due to other 
opioids increased substantially for both populations, at an 
FIGURE 1. A, Age-standardized opioid mortality rate for the white (red) and black (blue) US resident populations, 1979–2015. B, 
Rate ratio (white/black) of opioid mortality rates. Dots are estimated rate. Vertical bars represent 95% confidence interval. Solid 
lines are joinpoint model fits.
FIGURE 2. Age-standardized opioid mortality rates by general type of opioid: heroin (green), methadone (orange), or other opi-
oid (violet) for white (top) and black (bottom) US resident populations, 1979–2015. Vertical bars are 95% confidence intervals. 
Solid lines are joinpoint model fits.
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annual rate of 18% (95% CI = 1, 39) for whites and 34% (95% 
CI = 2, 77) for blacks.
Opioid types can be further disaggregated during the 
period 1999–2015, due to the ICD-10 coding details (Table 2 
and Figure 3). In addition to heroin and methadone, the ICD-
10 also identifies opium (not analyzed due to low counts), 
natural/semi-synthetic opioids (e.g., oxycodone and hydro-
codone), synthetic opioids other than methadone (e.g., fen-
tanyl and tramadol), and unspecified opioids. The “other” 
opioid category defined above mainly consists of natural 
and semi-synthetic opioids and non-methadone synthetic 
opioids.
Trends in mortality due to natural/semi-synthetic 
opioids differ by race. By 2015, the natural opioid mortal-
ity rate for whites was more than double that for blacks, at 
4.6 compared to 2.1. The rate for blacks increased steadily 
by 8% (95% CI = 8, 9) per year from 1999 to 2015. The 
white rate increased by 13% (95% CI = 12, 14) per year 
in 1999–2010, then leveled out in 2010–2015 at 1% (95% 
CI = −2, 3). The differential increase in natural opioid mor-
tality by race explains the increase in the rate ratio from 
1999 to 2010.
The synthetic opioid mortality rate was 0.30 for whites 
and 0.12 for blacks in 1999 and increased an average of 17% 
(95% CI = 13, 21) for whites and 15% (95% CI = 1, 32) for 
blacks. For whites, the synthetic mortality rate increased 79% 
per year (95% CI = 50, 112) from 2013 to 2015, largely due 
to fentanyl, often taken in combination with heroin.31 While 
the confidence interval is wide and imprecise, the synthetic 
mortality rate for blacks was 107 (95% CI, −15, 404).
DISCUSSION
The opioid epidemic can be divided into three waves 
between 1979 and 2015. During the first wave, from 1979 
to the mid-1990s, opioid mortality was higher for the black 
population, but rates of increase were similar for both popula-
tions and largely driven by heroin. During the second wave, 
from the mid-1990s to 2010, the opioid epidemic expanded 
quickly within the white population while opioid mortality 
remained stable in the black population. As a consequence, 
the racial gradient of risk reversed in 2000, and by 2010, the 
opioid mortality rate were over 2 times higher for whites than 
for blacks. During this period, the opioid epidemic was driven 
largely by non-heroin and non-methadone opioids (i.e., pre-
scription painkillers). Lastly, from about 2010 to 2015, the 
opioid mortality rate grew rapidly for both the black and white 
populations. This third wave has similarities to the first wave, 
as the mortality increase has been driven by heroin, and more 
recently synthetic opioids, in both populations. However, 
recent death rates due to heroin and synthetic opioids have 
reached unprecedented levels, increasing by an average of at 
least 30% per year since 2010, with further acceleration since 
2013.
As reported in previous literature,4 the acceleration in 
the mortality increase for whites since 1990 has been closely 
tied to an increase in the number of prescription drugs and the 
use of opioid pain medication, prompting several initiatives 
to curb the improper use of these painkillers. For example, in 
2010, OxyContin was reformulated to be less easily abused. 
In addition, there have been other government-led initiatives 
such as Prescription Drug Monitoring Programs, Medicaid 
FIGURE 3. Opioid mortality rates for International Classification of Diseases (ICD)-10 years (1999–2015) by type for white (top) 
and black (bottom) US resident populations. Opioid types include heroin (green), methadone (orange), natural/semi-natural 
opioids (purple), synthetic opioids (pink), and unspecified opioids (light green). Vertical bars are 95% confidence intervals. Solid 
lines are joinpoint model fits.
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Lock-in programs and pain clinic laws, which sought to limit 
access and deter overuse of prescription opioids. These initia-
tives may explain the leveling of the natural/semi-synthetic 
opioid mortality rate that is observed since 2010.
The focus on restricting the supply of prescription opi-
oids without concurrently reducing demand, however, appears 
to be associated with a shift from prescription painkillers to 
heroin and other illicit opioids. In recent years, the supply of 
both heroin and illegally manufactured fentanyl has increased 
in the United States.32,33 The increased availability and afford-
ability of illicit opioids has led to many users substituting 
heroin/fentanyl for prescription opioids. Previous research has 
demonstrated a clear pathway of addiction from prescription 
opioids to heroin.34 The Centers for Disease Control and Pre-
vention reported that those addicted to opioid painkillers are 
40 times more likely to be also addicted to heroin.35
However, the substitution of heroin for prescription opi-
oids does not explain the recent rapid increase in the heroin 
and synthetic opioid mortality rates seen in the black popula-
tion. Indeed, our findings show that the opioid mortality rate 
for blacks more than doubled in 5 years, even without a his-
tory of high prescription opioid mortality. Increased heroin 
mortality in more recent years is likely to be partly a conse-
quence of the increased availability and affordability of heroin 
since 2010.36 However, more recent increases in overdoses are 
likely to be driven by the increased potency of heroin, which 
is now often mixed with fentanyl.34
In addition to physician training and restrictions to the 
supply of prescription opioids, recent policies to curb the opi-
oid epidemic have included comprehensive efforts such as 
harm reduction and early addiction treatment.37 For example, 
access to naloxone, a drug designed to rapidly reverse the 
effects of opioid overdose, has been shown to reduce opioid 
mortality when expanded in settings where overdoses are 
more likely to occur.38,39 Local interventions have expanded 
naloxone access by equipping law enforcement officers,40 
schools,41 and libraries.42 Similarly, there has been renewed 
interest in safe injection sites, where opioid users inject under 
the supervision of medical personnel,43 which have been 
shown to reduce opioid overdose deaths44 without an increase 
in drug trafficking or crime.45 Effectively addressing the epi-
demic will continue to require a better understanding of social 
and economic determinants of opioid use and the impact of 
both supply-side and demand-side interventions.46,47
Our work contributes to the existing literature on under-
standing the opioid epidemic in three main ways. First, we 
presented an analysis of opioid mortality over an extended 
time frame, analyzing an additional 20 years of data prior to 
1999, when published studies usually begin. This longer time 
series highlights similarities between historical conditions and 
the most recent wave of the epidemic. Second, we focused our 
analysis on differences in opioid mortality by race, whereas 
previous research tends to focus on trends in the total popula-
tion, or in the white population only, thereby omitting some 
key racial differences in the epidemic over time. Finally, 
examining trends by type of opioid provides evidence of shifts 
in the epidemic from heroin to prescription drugs to heroin 
and fentanyl.
The current opioid epidemic in the United States is 
unprecedented compared to previous drug crises, in terms of 
the number of people affected and the rate of increase in over-
dose deaths. Our findings show that the nature of the epidemic 
has changed substantially over the past 35 years, shifting from 
relatively low heroin mortality, to a prescription drug problem 
in the white population, and more recently to a heroin/fen-
tanyl epidemic affecting both the black and the white popu-
lations. In particular, since 2010, increases in mortality have 
been similar in both populations. The different patterns in the 
opioid epidemic by race suggest the need for targeted policy 
interventions to account for the distinctive pathways to addic-
tion. A better understanding of racial differences and how they 
relate to the use of other drugs, place of residence, and socio-
economic status is necessary to improve health interventions 
and rehabilitation programs across the country.
Limitations
This study has several limitations. First, differences in 
cause of death reporting between blacks and whites could 
affect estimates of the rate ratio. Recent research has indicated 
that opioid mortality is underreported by about 24% nationally 
and that the extent of underreporting varies by geography.48 In 
particular, increases in heroin mortality were underreported 
in southern states such as Louisiana and Alabama, with large 
black populations, which may affect estimates of heroin mor-
tality among the black population, especially if this geographic 
effect is aggravated by further differential reporting by race. 
For example, if medical examiners are more likely to classify 
deaths of whites as due to an “unspecified drug” (ICD-10 code 
T50.9) rather than to opioids, the rate ratio estimate may be 
too conservative. Conversely, classifying black opioid deaths 
as an “unspecified drug” would make our rate ratio estimate 
too higher. The misclassification of race on death certificates 
could also affect the calculation of opioid mortality. However, 
although no validation studies have been carried out to exam-
ine the accuracy of coding of opioid deaths by race, an analy-
sis of all causes of death showed that the effect on mortality 
of the misclassification of race on death certificates is small.49
Second, the jump joinpoint model assumes that the 
underlying trend remains the same during the ICD-9 to ICD-
10 transition. While there are no validation studies on the 
effect of the ICD change on opioid deaths specifically, the 
comparability ratio of accidental injuries (under which acci-
dental overdose—the overwhelming case of overdoses—is 
categorized) is estimated to be 1.03, which suggests that death 
classifications are reasonably comparable.50 Unfortunately, 
the classification change occurred as the epidemic was accel-
erating, and so quantifying this effect is difficult without fur-
ther validation.
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Last, it is important to note that fentanyl mortality rates 
may be underestimated, as a specific toxicology test must be 
requested by the coroner to determine the drug’s presence. 
Indeed, the observed increase in fentanyl deaths since 2013 
is likely attributable, at least in part, to improved detection 
through post-mortem investigations due to increased aware-
ness in the medical community.51
CONCLUSION
Over the period 1979 to 2015, age-standardized opioid 
mortality rates increased for both the white and the black pop-
ulations. Although rates of increase were initially similar in the 
two populations and driven by heroin, the period 1993–2010 
saw a rapid increase in opioid mortality for whites, largely 
due to prescription painkillers. Since 2010, opioid mortality 
has been increasing rapidly in both groups, largely driven by 
increases in heroin and synthetic opioids.
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